Gsk3368715 closed clinical trial
WebClinical Trials Detail Study #2024-0666 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of …
Gsk3368715 closed clinical trial
Did you know?
WebMay 23, 2011 · GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers … WebApr 11, 2024 · This study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), food effect and preliminary clinical activity of GSK33368715 in participants with …
WebFeb 19, 2024 · Evidence that GSK was rethinking plans for PRMT1 inhibitor GSK3368715 emerged last year, when the company wrapped up an early-phase study in solid tumor and diffuse large B-cell lymphoma patients 15 months ahead of schedule. The trial enrolled 31 subjects, well down on the 215 patients GSK originally planned to recruit. WebSep 10, 2024 · First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) March 1, 2024 updated by: …
WebApr 8, 2024 · The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, wh... Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP … WebOct 1, 2024 · Results. Fifty-four pts with a median age of 60 (range 21 – 81) received at least one dose of drug. The most common tumor types were adenoid cystic carcinoma …
WebJul 29, 2024 · GSK3368715 induces time- and dose-dependent accumulation of DLBCL cells in sub-G 1. In contrast, the cytostatic OCI-Ly1 line accumulation of sub-G 1 only detects at the highest concentration of GSK3368715. In vivo, GSK3368715 can completely inhibit tumor growth or cause regressions of tumor models.
WebJan 25, 2024 · Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2024 Jul 8;36 (1):100-114.e25. doi: 10.1016/j.ccell.2024.05.014. Epub 2024 Jun 27. PMID: 31257072. 制版人：Kira 特别声明：以上内容 (如有图片或视频亦包括在内)为自媒体平台“ … roofing shingles 20 yearWebNational Center for Biotechnology Information roofing shingles calculator 2020WebFeb 8, 2024 · The company is seeking to develop the drug in combination with GlaxoSmithKline's PRMT inhibitor GSK3368715, among other drugs. GSK and Ideaya began a collaboration last year to co-develop synthetic lethality drugs. GSK paid $100 million in cash and bought $20 million of Ideaya common stock upfront for the option to … roofing shingles certainteedWebJul 8, 2024 · The current report describes GSK3368715 (EPZ019997), a potent, reversible type I PRMT inhibitor with anti-tumor effects in human cancer models. Inhibition of … roofing shingles at home depotWebSep 10, 2024 · First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) GlaxoSmithKline 20 May 2024 First Received: September 10, 2024 Last Updated: May 20, 2024 Phase: Phase 1 Start Date: October 22, 2024 Overall Status: Terminated Estimated Enrollment: 31 Overview roofing shingles colors for housesWebMay 18, 2024 · Since the dysregulation of protein arginine methylation is closely associated with cancer development, protein arginine methyltransferases (PRMTs) have garnered significant interest as novel... roofing shingles companiesWebDec 24, 2024 · GSK3368715 is a potent reversible inhibitor of all five type I PRMTs. Profiling with this compound across a panel of 249 cancer cell lines, representing 12 tumor types demonstrated cytotoxicity... roofing shingles comparison